Ironwood Pharmaceuticals is headquartered in Cambridge, US

Co-Founder

Co-Founder and Vice President of Program Management

Ironwood Pharmaceuticals has an office in Cambridge

Cambridge, US (HQ)

301 Binney St

Ironwood Pharmaceuticals's revenue was reported to be $52.2 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 52.2 m |

## Net income (Q1, 2017) | (52.5 m) |

## EBIT (Q1, 2017) | (39.7 m) |

## Market capitalization (17-Aug-2017) | 2.2 b |

## Cash (31-Mar-2017) | 133.3 m |

Ironwood Pharmaceuticals's current market capitalization is $2.2 b.

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Revenue | 22.9 m | 76.4 m | 149.6 m | 274 m |

## Revenue growth, % | 234% | 96% | 83% | |

## Gross profit | 15.7 m | 50.9 m | 149.5 m | |

## Gross profit Margin, % | 69% | 67% | 100% | |

## R&D expense | 139.5 m | |||

## General and administrative expense | 173.3 m | |||

## Operating expense total | 267.7 m | 220.2 m | 251.6 m | 312.8 m |

## EBIT | (252 m) | (169.4 m) | (102.1 m) | (51.9 m) |

## EBIT margin, % | (1101%) | (222%) | (68%) | (19%) |

## Interest expense | (39.2 m) | |||

## Net Income | (272.8 m) | (189.6 m) | (142.7 m) | (81.7 m) |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 52.2 m | ||||||||

## Cost of goods sold | 10.5 m | 12 k | 8.2 m | 12 k | 12 k | ||||

## R&D expense | 22.1 m | 25.1 m | 26.6 m | 28.6 m | 25.8 m | 31.8 m | 31.7 m | 37.5 m | 33.7 m |

## General and administrative expense | 29.3 m | 28.5 m | 30.3 m | 33 m | 30.4 m | 36.2 m | 36.9 m | 45 m | 55.6 m |

## Operating expense total | 51.4 m | 53.7 m | 57 m | 61.6 m | 56.3 m | 68 m | 68.6 m | 82.5 m | 89.3 m |

## EBIT | (55.1 m) | (36.7 m) | (28.1 m) | (42 m) | (26.2 m) | (2 m) | (15.3 m) | (28.3 m) | (39.7 m) |

## EBIT margin, % | (76%) | ||||||||

## Interest expense | (5.3 m) | (5.3 m) | (5.2 m) | (5.9 m) | (10 m) | (9.9 m) | (9.8 m) | (9.8 m) | (9 m) |

## Net Income | (60.4 m) | (42 m) | (33.2 m) | (48 m) | (47.4 m) | (13.3 m) | (21.7 m) | (33.2 m) | (52.5 m) |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Cash | 75.5 m | 74.3 m | 261.3 m | 54 m |

## Accounts Receivable | 513 k | 10 k | 2.9 m | 933 k |

## Inventories | 6.2 m | 10.6 m | 6.3 m | 1.1 m |

## Current Assets | 229.1 m | 289.7 m | 500.2 m | 380.2 m |

## PP&E | 37.4 m | 29.8 m | 21.1 m | 20.5 m |

## Goodwill | 785 k | |||

## Total Assets | 279 m | 333.5 m | 619.1 m | 709.8 m |

## Accounts Payable | 10.1 m | 9.8 m | 8.6 m | 17.7 m |

## Total Debt | 175.8 m | 6.2 m | ||

## Current Liabilities | 41 m | 60.5 m | 76.5 m | 91.1 m |

## Common Stock | 103 k | 125 k | 127 k | 133 k |

## Additional Paid-in Capital | 815.9 m | 1.1 b | 1.2 b | 1.3 b |

## Retained Earnings | (777.8 m) | (967.4 m) | (1.1 b) | (1.2 b) |

## Total Equity | 38.2 m | 88.6 m | 95.1 m | 66.7 m |

## Debt to Equity Ratio | 4.6 x | 0.1 x | ||

## Debt to Assets Ratio | 0.6 x | 0 x | ||

## Financial Leverage | 7.3 x | 3.8 x | 6.5 x | 10.6 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 95.4 m | 51.3 m | 63.7 m | 256.5 m | 248.1 m | 280.9 m | 277.3 m | 182.9 m | 133.3 m |

## Accounts Receivable | 380 k | 862 k | 1.1 m | 2.6 m | 908 k | 1.3 m | 1.2 m | 1.2 m | |

## Inventories | 13 m | 13 m | 5 m | 1.5 m | |||||

## Current Assets | 325.8 m | 304.1 m | 263.9 m | 527 m | 505.8 m | 495.7 m | 386.1 m | 382.8 m | 357.9 m |

## PP&E | 33.6 m | 30.4 m | 27.5 m | 25 m | 23.2 m | 19.4 m | 17.9 m | 18.8 m | 18.6 m |

## Goodwill | 649 k | 649 k | 785 k | ||||||

## Total Assets | 371.1 m | 346.2 m | 305.5 m | 653.9 m | 613.4 m | 603.3 m | 700.2 m | 732 m | 701.3 m |

## Accounts Payable | 3.4 m | 6.1 m | |||||||

## Current Liabilities | 41.6 m | 54.1 m | 59.8 m | 62.1 m | 67.8 m | 78.1 m | 91 m | 95.3 m | 78.9 m |

## Common Stock | 120 k | 124 k | 126 k | 126 k | 127 k | 128 k | 130 k | 131 k | 134 k |

## Additional Paid-in Capital | 1 b | 1 b | 1.1 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.2 b | 1.3 b |

## Retained Earnings | (887.8 m) | (929.8 m) | (1 b) | (1 b) | (1.1 b) | (1.1 b) | (1.1 b) | (1.2 b) | (1.2 b) |

## Total Equity | 141.8 m | 108.2 m | 68.2 m | 140.3 m | 100.5 m | 90.9 m | 81.4 m | 59.5 m | 29.6 m |

## Financial Leverage | 2.6 x | 3.2 x | 4.5 x | 4.7 x | 6.1 x | 6.6 x | 8.6 x | 12.3 x | 23.7 x |

USD | FY, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|

## Net Income | (272.8 m) | (189.6 m) | (142.7 m) | (81.7 m) |

## Depreciation and Amortization | 11.7 m | 12.3 m | 11.6 m | 10.3 m |

## Accounts Receivable | (1.7 m) | (24 m) | (29 m) | (10.3 m) |

## Inventories | (52 k) | (3.9 m) | 2.6 m | (3.1 m) |

## Accounts Payable | (11.7 m) | 1.4 m | ||

## Cash From Operating Activities | (273.4 m) | (155.6 m) | (106.9 m) | (25.4 m) |

## Purchases of PP&E | (9.6 m) | (3.5 m) | (4 m) | (4.2 m) |

## Cash From Investing Activities | (101.4 m) | (56.6 m) | ||

## Cash From Financing Activities | 313.6 m | 210.9 m | 303.1 m | (4.2 m) |

## Interest Paid | 18.4 m | 19.6 m | 22.7 m | 24.5 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (60.4 m) | (42 m) | (33.2 m) | (48 m) | (47.4 m) | (13.3 m) | (21.7 m) | (33.2 m) | (52.5 m) |

## Accounts Receivable | 380 k | 862 k | 1.1 m | 2.6 m | 908 k | 1.3 m | 1.2 m | 1.2 m | |

## Inventories | 13 m | 13 m | 5 m | 1.5 m | |||||

## Accounts Payable | 3.4 m | 6.1 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 77.4 k |

## Financial Leverage | 23.7 x |

Source: 16 public H-1B filings from Ironwood Pharmaceuticals